ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

ACAD Company Profile and Key Details

NASDAQ : ACAD

ACADIA Pharmaceuticals Inc.

$16.16

-0.46-2.77%

Open: 2:34 PM

62.35

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

ACAD Stock Price Chart

Stock Price Today

ACADIA Pharmaceuticals Inc. (ACAD) stock declined over -2.77%, trading at $16.16 on NASDAQ, down from the previous close of $16.62. The stock opened at $16.25, fluctuating between $16.02 and $16.43 in the recent session.

Stock Snapshot

16.62

Prev. Close

16.25

Open

2.7B

Market Cap

166.79M

Number of Shares

16.015

Day Low

16.43

Day High

11.88

P/E Ratio

99.22%

Free Float in %

1.36

EPS (TTM)

2.62

Book Value

-0.14

Cash Flow per Share

595.73K

Volume

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 02, 2025	16.21	16.73	16.18	16.62	1.96M
Apr 01, 2025	16.56	16.77	16.15	16.32	2.02M
Mar 31, 2025	16.71	16.88	16.28	16.61	1.69M
Mar 28, 2025	17.16	17.22	16.92	17.07	872.12K
Mar 27, 2025	17.10	17.31	16.94	17.19	1.37M
Mar 26, 2025	17.05	17.09	16.86	17.03	902.7K
Mar 25, 2025	17.21	17.39	16.95	17.11	1.01M
Mar 24, 2025	17.20	17.50	17.02	17.23	1.07M
Mar 21, 2025	17.04	17.31	16.67	16.79	4.04M
Mar 20, 2025	17.10	17.43	17.10	17.18	1.52M
Mar 19, 2025	17.26	17.60	17.07	17.29	1.21M
Mar 18, 2025	16.96	17.45	16.79	17.28	1.33M
Mar 17, 2025	17.54	17.66	17.03	17.20	1.63M
Mar 14, 2025	16.91	17.70	16.70	17.50	1.95M
Mar 13, 2025	16.67	16.91	16.59	16.78	1.29M
Mar 12, 2025	17.23	17.39	16.76	16.77	1.59M
Mar 11, 2025	17.10	17.45	16.86	17.19	1.56M
Mar 10, 2025	17.35	17.68	17.07	17.19	1.79M
Mar 07, 2025	17.62	17.86	17.33	17.56	1.37M
Mar 06, 2025	17.85	18.15	17.59	17.61	1.67M

Contact Details

San Diego, CA 92130

United States

Website: https://www.acadia-pharm.comContact: 858 558 2871

About Company

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Frequently Asked Questions

What is the current ACADIA Pharmaceuticals Inc. (ACAD) stock price?

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) stock price is $16.16 in the last trading session. During the trading session, ACAD stock reached the peak price of $16.43 while $16.02 was the lowest point it dropped to. The percentage change in ACAD stock occurred in the recent session was -2.77% while the dollar amount for the price change in ACAD stock was -$0.46.

ACAD's industry and sector of operation?

The NASDAQ listed ACAD is part of Biotechnology industry that operates in the broader Healthcare sector. ACADIA Pharmaceuticals Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ACAD?

Dr. Srdjan R. Stankovic M.D., M.S.P.H.
Pres
Mr. Austin D. Kim
Executive Vice President, Gen. Counsel & Sec.
Mr. James K. Kihara
Vice President, Chief Accounting Officer & Corporation Controller
Mr. Bob Mischler
Senior Vice President of Strategy & Technology Operations
Mr. Mark C. Johnson
Vice President of Investor Relations
Ms. Julie Fisher
Senior Vice President of Marketing & Commercial Strategy
Mr. Mark C. Schneyer
Executive Vice President & Chief Financial Officer
Dr. Mary Ellen Turner
Senior Vice President of Pharmacovigilance & Corporation Safety Officer
Mr. Rob Ackles
Senior Vice President & Chief People Officer
Ms. Holly Valdiviez
Senior Vice President & Head of Sales
Ms. Ponni Subbiah M.D., M.P.H.
SVice President, Global Head of Medical Affairs & Chief Medical Officer
Mr. Brendan P. Teehan
Executive Vice President, Chief Operating Officer & Head of Commercial
Mr. Stephen R. Davis J.D.
Pres, Chief Executive Officer & Director

How ACAD did perform over past 52-week?

ACAD's closing price is 17.46% higher than its 52-week low of $14.15 where as its distance from 52-week high of $20.68 is -19.63%.

How many employees does ACAD have?

Number of ACAD employees currently stands at 653.

Link for ACAD official website?

Official Website of ACAD is: https://www.acadia-pharm.com

How do I contact ACAD?

ACAD could be contacted at phone 858 558 2871 and can also be accessed through its website. ACAD operates from 12830 El Camino Real, San Diego, CA 92130, United States.

How many shares of ACAD are traded daily?

ACAD stock volume for the day was 595.73K shares. The average number of ACAD shares traded daily for last 3 months was 1.81M.

What is the market cap of ACAD currently?

The market value of ACAD currently stands at $2.70B with its latest stock price at $16.16 and 166.79M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

Employees	653
Beta	0.43
Sales or Revenue	$726.44M
5Y Sales Change%	1.508%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology